Wintest
6721
D. Western Therapeutics Institute
4576
Ridge-i
5572
Hamee
3134
River Eletec
6666
(FY)Jul 31, 2024 | (Q4)Jul 31, 2024 | (Q3)Apr 30, 2024 | (Q2)Jan 31, 2024 | (Q1)Oct 31, 2023 | (FY)Jul 31, 2023 | (Q4)Jul 31, 2023 | (Q3)Apr 30, 2023 | (Q2)Jan 31, 2023 | (Q1)Oct 31, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 12.30%4.68B | -7.03%1.07B | 4.79%1.12B | 27.62%1.17B | 28.04%1.32B | 18.88%4.17B | 19.22%1.15B | 6.80%1.07B | 6.43%919.42M | 52.18%1.03B |
Cost of revenue | 13.51%3.61B | -7.93%818.99M | 6.63%859.91M | 29.08%897.15M | 31.05%1.03B | 20.10%3.18B | 21.63%889.51M | 6.48%806.42M | 5.70%695.06M | 57.45%786.31M |
Gross profit | 8.42%1.07B | -4.00%251.27M | -0.91%258.53M | 23.11%276.22M | 18.28%286.49M | 15.14%989.22M | 11.68%261.73M | 7.78%260.91M | 8.78%224.37M | 37.25%242.22M |
Operating expense | 20.82%1.02B | 6.99%283.49M | 18.10%240.65M | 28.50%258.65M | 36.48%233.31M | 31.62%840.98M | 51.98%264.97M | 26.58%203.77M | 27.84%201.29M | 16.94%170.95M |
Operating profit | -61.96%56.39M | -892.67%-32.22M | -68.71%17.88M | -23.90%17.56M | -25.39%53.17M | -32.68%148.24M | -105.41%-3.25M | -29.53%57.14M | -52.72%23.08M | 135.19%71.27M |
Net non-operating interest income (expenses) | -653.46%-4.03M | -745.63%-1.35M | -299.19%-982K | -571.21%-886K | -27,100.00%-810K | -26,650.00%-535K | -15,900.00%-160K | -12,400.00%-246K | -4,300.00%-132K | 3K |
Non-operating interest income | -97.64%12K | -99.60%2K | 20.00%6K | --0 | 33.33%4K | 7,157.14%508K | --500K | 25.00%5K | --0 | 0.00%3K |
Non-operating interest expense | 287.63%4.04M | 105.30%1.36M | 293.63%988K | 571.21%886K | --814K | 11,488.89%1.04M | 65,900.00%660K | 12,450.00%251K | 4,300.00%132K | --0 |
Net investment income | 2.45M | |||||||||
Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
Gain(Loss) on derecognition of available-for-sale financial assets | 0 | -824K | 0 | 0 | ||||||
Income from associates and other participating interests | 273.82%8.93M | -5.55M | -7.56M | 10.11M | 11.92M | -5.14M | ||||
Special income (charges) | -232.12%-2.48M | -6,836.00%-1.68M | -5,216.00%-3.99M | 583.49%745K | 34.99%2.45M | 2,052.08%1.87M | -85.21%25K | 80.92%-75K | 309.62%109K | 908.33%1.82M |
Less:Other special charges | -345.80%-3.24M | ---483K | ---52K | ---798K | -162.45%-1.91M | -185.43%-727K | --0 | --0 | --0 | -185.43%-727K |
Less:Write off | 598.43%5.72M | 8,768.00%2.17M | 5,285.33%4.04M | 148.62%53K | 50.18%-542K | -51.92%-1.15M | 88.32%-25K | -80.92%75K | -212.37%-109K | -5.53%-1.09M |
Other non-operating income (expenses) | 8,755.81%3.81M | 218.07%1.09M | 25.42%1.19M | 409K | 5,789.47%1.12M | 100.32%43K | 93.28%-924K | 8,718.18%948K | 0 | -92.18%19K |
Income before tax | -56.41%62.62M | -220.50%-39.71M | -89.14%6.54M | 22.93%27.94M | -7.19%67.85M | -30.49%143.66M | -126.70%-12.39M | -25.36%60.21M | -53.48%22.73M | 137.95%73.11M |
Income tax | -49.50%37.47M | -84.89%1.66M | -77.45%5.18M | -35.04%8.26M | -18.77%22.38M | 6.44%74.2M | 19.21%10.98M | -25.47%22.96M | -28.54%12.71M | 131.33%27.55M |
Net income | -63.79%25.15M | -77.01%-41.37M | -96.34%1.36M | 96.42%19.69M | -0.18%45.48M | -49.29%69.46M | -162.84%-23.37M | -25.30%37.26M | -67.76%10.02M | 142.14%45.56M |
Net income continuous operations | -63.79%25.16M | -77.00%-41.37M | -96.34%1.36M | 96.43%19.69M | -0.18%45.48M | -49.29%69.46M | -162.84%-23.38M | -25.30%37.26M | -67.76%10.02M | 142.14%45.56M |
Noncontrolling interests | ||||||||||
Net income attributable to the company | -63.79%25.15M | -77.01%-41.37M | -96.34%1.36M | 96.42%19.69M | -0.18%45.48M | -49.29%69.46M | -162.84%-23.37M | -25.30%37.26M | -67.76%10.02M | 142.14%45.56M |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | -63.79%25.15M | -77.01%-41.37M | -96.34%1.36M | 96.42%19.69M | -0.18%45.48M | -49.29%69.46M | -162.84%-23.37M | -25.30%37.26M | -67.76%10.02M | 142.14%45.56M |
Gross dividend payment | ||||||||||
Basic earnings per share | -63.83%23.12 | -76.47%-38.03 | -96.32%1.26 | 98.57%18.09 | -0.74%41.8 | -56.51%63.92 | -154.50%-21.55 | -36.22%34.25 | -72.78%9.11 | 107.85%42.11 |
Diluted earnings per share | -63.83%23.12 | -76.49%-38.0332 | -96.34%1.2539 | 98.57%18.09 | -0.74%41.8 | -56.51%63.92 | -160.75%-21.55 | -36.25%34.2332 | -72.78%9.11 | 107.85%42.11 |
Dividend per share | ||||||||||
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |